COPD (HFO Propellant)

AstraZeneca (AZ002) D5985C00002

This study will investigate the effect on lung function of an approved COPD treatment (BGF, with HFA propellant) compared to BGF formulated with a new propellant (HFO).

The purpose of this study is to demonstrate that the lung function effect from orally inhaled triple therapy inhaler (BGF) delivered via HFO propellant is equivalent to the lung function effect from orally inhaled triple therapy inhaler (BGF) delivered via HFA propellant in participants with COPD. BGF is used to help improve and reduce the number of COPD flare-ups, and to open the airways of the lungs.The study duration for each participant will be approximately 15 to 16 weeks.

To Participate in this study you must:

Be 40 to 80 years old
Have a documented history of physician-diagnosed COPD
Have been receiving inhaled maintenance therapies for the management of their COPD for at least 4 weeks
Be a current or former smoker with a history of at least 10 pack-years of tobacco smoking